Follow-up study of 281 schizophrenic patients treated with high dosage fluphenazine decanoate.
281 newly admitted female schizophrenic patients were treated with high dosage fluphenazine decanoate intramuscularly, starting with 250 mg per injection together with antiparkinsonian and antidepressant drugs. On a set day the 3 groups 'with neuroleptics' (NL) (n = 54), 'without NL' (n = 152) and 'relapsed when without NL' (n = 42) were compared concerning age, diagnosis, hereditary disposition, first admission and readmissions, number of admissions and global judgement. From the differences no clear conclusion for practical clinical work could be obtained. The good tolerance is discussed using the list of side effects including tardive dyskinesia and laboratory data.
D000367:Age Factors; D004409:Dyskinesia, Drug-Induced / Q000209:etiology; D005260:Female; D005476:Fluphenazine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D012008:Recurrence; D012559:Schizophrenia / Q000188:drug therapy* / Q000235:genetics
C011825:fluphenazine depot; D005476:Fluphenazine